KR102270521B1 - 구토억제 서방형 고체 제형 - Google Patents

구토억제 서방형 고체 제형 Download PDF

Info

Publication number
KR102270521B1
KR102270521B1 KR1020157028825A KR20157028825A KR102270521B1 KR 102270521 B1 KR102270521 B1 KR 102270521B1 KR 1020157028825 A KR1020157028825 A KR 1020157028825A KR 20157028825 A KR20157028825 A KR 20157028825A KR 102270521 B1 KR102270521 B1 KR 102270521B1
Authority
KR
South Korea
Prior art keywords
ondansetron
delete delete
drug
release
hypromellose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157028825A
Other languages
English (en)
Korean (ko)
Other versions
KR20150127253A (ko
Inventor
레자 파티
길리어드 라데이
Original Assignee
레드힐 바이오파마 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102270521(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 레드힐 바이오파마 엘티디 filed Critical 레드힐 바이오파마 엘티디
Publication of KR20150127253A publication Critical patent/KR20150127253A/ko
Application granted granted Critical
Publication of KR102270521B1 publication Critical patent/KR102270521B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020157028825A 2013-03-14 2014-03-14 구토억제 서방형 고체 제형 Active KR102270521B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782395P 2013-03-14 2013-03-14
US61/782,395 2013-03-14
PCT/IB2014/001633 WO2014181195A2 (en) 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms

Publications (2)

Publication Number Publication Date
KR20150127253A KR20150127253A (ko) 2015-11-16
KR102270521B1 true KR102270521B1 (ko) 2021-06-30

Family

ID=51528070

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157028825A Active KR102270521B1 (ko) 2013-03-14 2014-03-14 구토억제 서방형 고체 제형

Country Status (19)

Country Link
US (5) US9636305B2 (https=)
EP (1) EP2983664B1 (https=)
JP (1) JP6282676B2 (https=)
KR (1) KR102270521B1 (https=)
CN (2) CN112274489A (https=)
AU (1) AU2014264342B2 (https=)
BR (1) BR112015022398B1 (https=)
CA (1) CA2905553C (https=)
CL (1) CL2015002666A1 (https=)
ES (1) ES2946985T3 (https=)
HK (1) HK1223012A1 (https=)
IL (1) IL241580B (https=)
MX (1) MX378261B (https=)
NZ (1) NZ712159A (https=)
PH (1) PH12015502093B1 (https=)
RU (1) RU2679448C2 (https=)
SG (1) SG11201507450TA (https=)
WO (2) WO2014184662A2 (https=)
ZA (1) ZA201506961B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636305B2 (en) 2013-03-14 2017-05-02 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms
SG11201607511WA (en) * 2014-03-11 2016-10-28 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
WO2020080875A1 (ko) * 2018-10-19 2020-04-23 주식회사 삼양바이오팜 아프레피탄트의 경구용 조성물
KR20250107210A (ko) * 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009829A2 (en) 2001-03-19 2003-02-06 L.A.M. Pharmaceutical Corporation Antiemetic, anti-motion sustained release drug delivery system
US20080113021A1 (en) 2006-10-25 2008-05-15 Robert Shen Ibuprofen composition
WO2008065424A1 (en) 2006-12-01 2008-06-05 Selamine Ltd Ramipril-amlodipine salt
US20080200508A1 (en) 2004-12-20 2008-08-21 Collegium Pharmaceutical, Inc. Pharmaceutical Compositions For Sleep Disorders
US20080299197A1 (en) 2005-12-29 2008-12-04 Osmotica Corp. Triple Combination Release Multi-Layered Tablet
WO2009118763A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20120128730A1 (en) 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
AU2084801A (en) 1999-12-09 2001-06-18 Alza Corporation Antiviral medication
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
GB0119012D0 (en) 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
GB0129489D0 (en) * 2001-12-10 2002-01-30 Quadrant Healthcare Uk Ltd Sustained-release compositions
US20050131045A1 (en) 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
NZ541009A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
US7829544B2 (en) 2003-11-14 2010-11-09 Senju Pharmaceutical Co., Ltd. Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac
CA2579767A1 (en) * 2004-04-30 2005-11-10 Astellas Pharma Inc. Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
US20070190141A1 (en) 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
BRPI0621996B8 (pt) 2006-08-18 2022-07-05 Evonik Roehm Gmbh preparação farmacêutica compreendendo um núcleo com um ingrediente ativo e com um ácido orgânico e/ou com o sal de um ácido orgânico, e um revestimento que envolve o núcleo e que compreende um ou mais copolímeros de (met)acrilato, e seu uso.
CN100584319C (zh) 2006-10-16 2010-01-27 北京科信必成医药科技发展有限公司 群孔释放渗透泵控释片及其制备方法
CN101568351B (zh) 2006-12-22 2012-05-30 3M创新有限公司 控制释放的组合物和方法
US20100196291A1 (en) 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
WO2010100657A2 (en) 2009-03-04 2010-09-10 Fdc Limited A novel oral controlled release dosage forms for water soluble drugs
RU2427389C2 (ru) * 2009-10-09 2011-08-27 Александр Владимирович Диковский Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей
BR112012013011A2 (pt) * 2009-11-30 2015-09-08 Aptalis Pharmatech Inc odt; composição de odt; método para a preparação de um tablete de odt multiparticulado, método para tratar ou prevenir náusea e vômito pós operatória ou náusea e vômito pós- alta por até 24 horas após a dosagem, método para tratar pu prevenir náusea por até 24 horas após a dosagem e método para tratar ou prevenir náusea e vômito associados a radioterapia em pacientes que recebem ou irradiação de corpo total, dose alta única ao abdômen, ou frações diárias ao abdômen por até 24 horas após a dosagem
MX2012007448A (es) * 2009-12-22 2012-09-12 Abbott Healthcare Private Ltd Composicion farmaceutica de liberacion controlada.
CA2784587A1 (en) 2009-12-28 2011-07-28 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
JP2013536832A (ja) 2010-08-30 2013-09-26 ルピン・リミテッド ミルナシプランの制御放出医薬組成物
US9636305B2 (en) 2013-03-14 2017-05-02 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009829A2 (en) 2001-03-19 2003-02-06 L.A.M. Pharmaceutical Corporation Antiemetic, anti-motion sustained release drug delivery system
US20080200508A1 (en) 2004-12-20 2008-08-21 Collegium Pharmaceutical, Inc. Pharmaceutical Compositions For Sleep Disorders
US20080299197A1 (en) 2005-12-29 2008-12-04 Osmotica Corp. Triple Combination Release Multi-Layered Tablet
US20080113021A1 (en) 2006-10-25 2008-05-15 Robert Shen Ibuprofen composition
WO2008065424A1 (en) 2006-12-01 2008-06-05 Selamine Ltd Ramipril-amlodipine salt
WO2009118763A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20120128730A1 (en) 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron

Also Published As

Publication number Publication date
BR112015022398B1 (pt) 2022-01-11
HK1223012A1 (zh) 2017-07-21
JP6282676B2 (ja) 2018-02-21
EP2983664A4 (en) 2017-01-04
CA2905553A1 (en) 2014-11-13
BR112015022398A2 (pt) 2017-07-18
US20140271851A1 (en) 2014-09-18
WO2014184662A2 (en) 2014-11-20
MX378261B (es) 2025-03-10
AU2014264342B2 (en) 2017-05-18
EP2983664B1 (en) 2023-04-19
EP2983664A2 (en) 2016-02-17
CA2905553C (en) 2021-04-06
ZA201506961B (en) 2017-03-29
ES2946985T3 (es) 2023-07-31
CN105530935A (zh) 2016-04-27
SG11201507450TA (en) 2015-10-29
MX2015012970A (es) 2016-04-11
NZ712159A (en) 2019-12-20
WO2014181195A2 (en) 2014-11-13
PH12015502093B1 (en) 2018-09-26
CL2015002666A1 (es) 2017-02-17
IL241580B (en) 2020-08-31
US20170189340A1 (en) 2017-07-06
CN112274489A (zh) 2021-01-29
WO2014184662A3 (en) 2015-04-02
US20200330392A1 (en) 2020-10-22
PH12015502093A1 (en) 2016-01-18
US9636305B2 (en) 2017-05-02
JP2016512493A (ja) 2016-04-28
RU2679448C2 (ru) 2019-02-11
KR20150127253A (ko) 2015-11-16
BR112015022398A8 (pt) 2019-11-26
WO2014181195A3 (en) 2015-12-17
US20140271887A1 (en) 2014-09-18
RU2015143993A (ru) 2017-04-20
RU2015143993A3 (https=) 2018-03-21
AU2014264342A1 (en) 2015-10-01
US20180028452A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
US8541026B2 (en) Sustained release formulations of opioid and nonopioid analgesics
US20160287580A1 (en) Sustained Release Monoeximic Formulations of Opioid and Nonopioid Analgesics
US20200330392A1 (en) Bimodal release ondansetron tablets and methods of treating nausea and vomiting
US20200253933A1 (en) Methods for treating diarrhea predominant irritable bowel syndrome
JP2018154586A (ja) 錠剤
HK40045804A (en) Antiemetic extended release solid dosage forms
HK1232432A1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
HK1232432B (zh) 用於治疗恶心、呕吐或腹泻症状的恩丹西酮缓释固体制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

D12-X000 Request for substantive examination rejected

St.27 status event code: A-1-2-D10-D12-exm-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6